Nisa Investment Advisors LLC Has $71,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Nisa Investment Advisors LLC boosted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 14.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,493 shares of the specialty pharmaceutical company’s stock after buying an additional 316 shares during the period. Nisa Investment Advisors LLC’s holdings in Collegium Pharmaceutical were worth $71,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Harbor Capital Advisors Inc. grew its position in shares of Collegium Pharmaceutical by 15.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 27,150 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 3,652 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the period. Principal Financial Group Inc. grew its holdings in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after buying an additional 64,958 shares in the last quarter. Franklin Resources Inc. increased its position in Collegium Pharmaceutical by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company’s stock worth $1,164,000 after buying an additional 3,620 shares during the period. Finally, Sanctuary Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 10.7% during the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after buying an additional 1,731 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Piper Sandler restated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $43.80.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $32.51 on Friday. Collegium Pharmaceutical, Inc. has a 1 year low of $28.39 and a 1 year high of $42.29. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 14.01 and a beta of 0.82. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm’s 50 day simple moving average is $30.98 and its 200 day simple moving average is $34.14.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.